• CGT Catapult appoints Chief Business Officer
    Jeanette Evans

Company News

CGT Catapult appoints Chief Business Officer

Oct 17 2023

Jeanette Evans has joined the Cell and Gene Therapy Catapult as Chief Business Officer (CBO), taking over from Sharon Brownlow. Jeanette is a senior business development executive with over 25 years' experience in the pharmaceutical industry including working for leading companies such as AstraZeneca and Merck.

Formerly Vice President Business Development with Adaptimmune, through collaborations and partnerships with industry and academia her team supported the advancement of Adaptimmune’s cell therapies for the treatment of patients with solid tumours.  

In her role as CBO Jeanette will be responsible for leading the CGT Catapult’s business development and legal teams, providing support as they work to establish and maintain collaborations with academics and industry.

Matthew Durdy, Chief Executive of the CGT Catapult, commented: “Jeanette’s extensive experience in business development and excellent track record in global transactions will be a welcome addition to our leadership team.

"We look forward to working with Jeanette as we continue to strengthen our partnerships and support for the advanced therapies sector.

"I would also like to thank Sharon Brownlow for all her work over these past few years, she has been vital to the growth and development of our work in the UK, and we wish her all the best for the future.”

More information online

Digital Edition

ILM 49.5 July

July 2024

Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...

View all digital editions


ADLM 2024

Jul 28 2024 San Diego, CA USA

InaLab 2024

Jul 30 2024 Jakarta, Indonesia


Jul 31 2024 Chengdu, China

ACS National Meeting - Fall 2024

Aug 18 2024 Denver, CO, USA


Aug 25 2024 Copenhagen, Denmark

View all events